AUS
NZ
UK
CA
USA
IND
Headlines
- Healthcare's Resilience: AbbVie and Merck, two prominent pharmaceutical companies, are well-positioned to navigate economic downturns due to their essential products and robust pipelines.
- AbbVie's Strategic Growth: AbbVie continues to perform well despite losing exclusivity on its best-selling drug, Humira, thanks to its strong portfolio and strategic acquisitions.
- Merck's Pipeline Strength: Merck, driven by the success of its top-selling drug Keytruda, is prepared for future challenges with innovative treatments and a strong dividend history.
Economic downturns are an inevitable part of the financial landscape. While predicting the timing and severity of recessions can be challenging, it is crucial to identify companies that can weather these storms effectively. Dividend-paying companies, particularly in essential industries, often stand out during such periods due to their stability and consistent returns.
Two such companies that demonstrate resilience and potential for steady performance even during economic challenges are AbbVie and Merck .
- AbbVie
Healthcare, particularly the pharmaceutical sector, is a critical industry known for its defensive nature. AbbVie (NYSE:ABBV) is a key player in this space, with a diverse portfolio of essential medicines. The company's lineup includes treatments like Skyrizi and Rinvoq in immunology, Venclexta and Imbruvica in oncology, and Vraylar and Qulipta in neuroscience.
Despite losing patent exclusivity on its blockbuster drug, Humira, AbbVie has managed to maintain solid financial health. In the second quarter, AbbVie reported a revenue increase of 4.3% year over year, totaling $14.5 billion. This performance reflects the company’s robust preparation and ability to manage challenges effectively.
AbbVie's strategic acquisitions, such as the recent $8.7 billion buyout of Cerevel Therapeutics, bolster its pipeline and position it for continued growth. The company’s current key drivers, Skyrizi and Rinvoq, are expected to generate over $27 billion in sales by 2027, showcasing AbbVie’s ability to sustain its revenue and dividend payouts through challenging economic times.
- Merck
Merck, (NYSE:MRK) another pharmaceutical giant, is also well-prepared to navigate economic uncertainty. Its leading product, Keytruda, is now the world’s top-selling drug, driving significant growth for the company. In the second quarter, Merck's revenue reached $16.1 billion, a 7% increase from the previous year, with Keytruda’s sales jumping 16% to $7.3 billion.
Merck is preparing for the expiration of Keytruda’s patent in 2028 by developing a subcutaneous version, which has the potential to generate significant revenue by 2030. Additionally, Merck’s pipeline includes promising new treatments like Winrevair, recently approved for pulmonary arterial hypertension, and various other oncology developments.
Merck’s strong dividend track record further reinforces its stability. The company has increased its payouts by 75% over the past decade, offering a forward yield of 2.65%. Merck’s ability to maintain its dividend and continue growing even during economic downturns highlights its resilience and appeal.
These two healthcare leaders, AbbVie and Merck, not only provide essential products but also offer dependable returns, making them solid options to consider during periods of economic uncertainty.
